Navigation Links
Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
Date:8/19/2007

- Reaching Critical Development Milestone

- Novel, Nasal Powder Vaccine Delivery Technology

IRVING, Texas, Aug. 15 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Nasdaq: CARN) today announced its subsidiary DelSite Biotechnologies, Inc. has initiated the animal toxicology studies of its GelVac(TM) nasal powder influenza vaccine, incorporating an H5N1 (bird flu) antigen.

The toxicology studies are a critical step during the vaccine development and will assess the vaccine safety in animals. Pending successful results of the toxicology studies and discussion with the antigen supplier, DelSite will file an IND for a phase I human safety study of the GelVac(TM) nasal powder H5N1 vaccine in late 2007. The toxicology studies are being conducted at a well-known contract research organization, using study protocols that have been reviewed by FDA. The GLP vaccine test articles were prepared and shipped to the study site according to the schedule established after receipt of the H5N1 antigen.

GelVac(TM) nasal powder platform is a novel, in-situ gelling powder formulation based on its GelSite(R) polymer technologies. A phase I human safety study on this platform (without an antigen) has been completed and found the platform safe and well tolerated. Preclinical studies with influenza antigen have shown that the nasal powder influenza vaccine is not only effective, but also provides distinct logistic advantages including room temperature stability and refrigeration-free distribution that are critical to pandemic preparedness.

Dr. Carlton Turner, CEO, commented, "With initiation of the animal toxicology studies, we have reached an important milestone for development of this first nasal powder influenza vaccine. Our team has done an outstanding job under a very tight schedule to produce the test materials and complete all logistic tasks for the study initiation. We anticipate the filing of IND paperwork before the end of 2007."

The development of GelVac(TM) nasal powder bird flu vaccine is partially funded by two grants from NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institute of Health), under the Department of Health and Human Services.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed August 14, 2007.


'/>"/>
SOURCE Carrington Laboratories, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
4. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
5. Malvern initiates European user group meetings for chemical imaging
6. NIEHS Researchers Identify Enzyme Critical in DNA Replication
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
9. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
10. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
11. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 Dr. ... und Stephen Schmidt werden ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen für ... dass neue Führungskräfte zum Team Sicherheit und ... vielfältige Erfahrungen mitbringen.  Dies wird die Geschäftseinheit ...
(Date:4/28/2016)... -- Dr. Vivek Ahuja , ... Ste phen Schmidt Join ... cloud-based software solutions for life sciences, today announced key new leaders ... of insight to a growing business.  This will bolster the company,s ... Phillips joined ArisGlobal in the position of Vice President - ...
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
Breaking Medicine Technology:
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE ... entirely on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower ... 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have ...
(Date:4/29/2016)... ... April 29, 2016 , ... International Dehydrated Foods, Inc. ... May 3 and 4 at the Doubletree by Hilton Hotel in Oak Brook, Illinois. ... marketing and applications technologies for protein ingredients. , At the seminar, IDF™ will offer ...
(Date:4/29/2016)... Wilmington, DE (PRWEB) , ... April 29, 2016 ... ... annual SMG Finance, which will be held May 16th to 18th at the ... all of the SMG managed facilities to collaborate on best practices in public ...
Breaking Medicine News(10 mins):